In 2017, the results of the CANTOS trials were published [10], documenting significant clinical benefits of Canakinumab, an interleukin-1 beta (IL-1β) neutralizing antibody, in the context of cardiovascular disease (CVD), which sparked renewed enthusiasm for the examination of anti-inflammatory therapies, including Colchicine and Methotrexate, in atherosclerosis [1,2,3,4,5,11]. The gene discussed is IL1B; the disease is atherosclerosis.